Catalog1 refs
Cagrilintide (AM833)
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.
Primary Uses
Weight Loss
Obesity (Monotherapy)
Obesity (CagriSema Combination)
Weight Loss in Diabetic Patients
Glycemic Control
Insulin Sensitivity
Satiety Enhancement
Protocol Reference
Dose
2.4mg weekly (after escalation)
Frequency
Once weekly
Half-life
~7 days (159-195 hours)
Route
Subcutaneous injection
Evidence
Extensively Studied
Research Models
Human
Also in Metabolic